Recent studies found that compared with the primary preventive population, the estimated per mg/dL relative risk reduction of Lp(a) in adverse events in patients with post-acute coronary syndrome (ACS) was greater, which indicated that Lp(a) reduction might potentially generate more benefits in the secondary prevention setting (2, 9). The gene discussed is LPA; the disease is acute coronary syndrome.